AU2001239658A1 - Method for producing a controlled-release preparation - Google Patents

Method for producing a controlled-release preparation

Info

Publication number
AU2001239658A1
AU2001239658A1 AU2001239658A AU3965801A AU2001239658A1 AU 2001239658 A1 AU2001239658 A1 AU 2001239658A1 AU 2001239658 A AU2001239658 A AU 2001239658A AU 3965801 A AU3965801 A AU 3965801A AU 2001239658 A1 AU2001239658 A1 AU 2001239658A1
Authority
AU
Australia
Prior art keywords
controlled
producing
pore
release preparation
forming agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001239658A
Inventor
Peter Fyhr
John Kendrup
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amarin Development AB
Original Assignee
Amarin Development AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amarin Development AB filed Critical Amarin Development AB
Publication of AU2001239658A1 publication Critical patent/AU2001239658A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a controlled-release pharmaceutical preparation including a drug-containing solid core having a coating thereon, said coating essentially consisting of a water Insoluble polymer with a predetermined amount of particles of a water soluble, pore-forming agent dispersed therein, wherein the pore-forming agent is selected from the group consisting of potassium bitartrate, creatine, aspartic acid, glutamic acid and inosine.
AU2001239658A 2000-03-31 2001-03-23 Method for producing a controlled-release preparation Abandoned AU2001239658A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0001151A SE0001151D0 (en) 2000-03-31 2000-03-31 Method of producing a controlled-release composition
SE0001151 2000-03-31
PCT/SE2001/000626 WO2001074336A1 (en) 2000-03-31 2001-03-23 Method for producing a controlled-release preparation

Publications (1)

Publication Number Publication Date
AU2001239658A1 true AU2001239658A1 (en) 2001-10-15

Family

ID=20279094

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001239658A Abandoned AU2001239658A1 (en) 2000-03-31 2001-03-23 Method for producing a controlled-release preparation

Country Status (8)

Country Link
US (2) US6974591B2 (en)
EP (2) EP1516616A1 (en)
JP (1) JP4963767B2 (en)
AT (1) ATE281156T1 (en)
AU (1) AU2001239658A1 (en)
DE (1) DE60106889T2 (en)
SE (1) SE0001151D0 (en)
WO (1) WO2001074336A1 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6551617B1 (en) * 2000-04-20 2003-04-22 Bristol-Myers Squibb Company Taste masking coating composition
CA2359812C (en) 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
US20030175349A1 (en) * 2001-01-30 2003-09-18 Council Of Scientific And Industrial Research Pharmaceutical compostion for extended/sustained release of a therapeutically active ingredient
US6960357B2 (en) 2001-05-25 2005-11-01 Mistral Pharma Inc. Chemical delivery device
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US9060941B2 (en) 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
KR20120034211A (en) * 2002-09-20 2012-04-10 안드렉스 랩스 엘엘씨 Pharmaceutical tablet
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
GB0518579D0 (en) * 2005-09-12 2005-10-19 Cr Technologies Llp Controlled delivery creatine formulations and method of using the same
NZ561375A (en) 2005-06-27 2011-06-30 Biovail Lab Int Srl Bupropion hydrobromide, and crystalline forms, compositions, and uses of this compound
BRPI0709606B8 (en) 2006-03-16 2021-05-25 Tris Pharma Inc orally administrable liquid suspension with modified release characteristics
TW200815045A (en) * 2006-06-29 2008-04-01 Jazz Pharmaceuticals Inc Pharmaceutical compositions of ropinirole and methods of use thereof
DE102006030860A1 (en) * 2006-07-04 2008-01-10 Universität Regensburg Oligomers of isonitrile metal complexes as triplet emitters for OLED applications
CN101766581B (en) * 2008-12-30 2012-08-15 北京科信必成医药科技发展有限公司 Diltiazem hydrochloride timing controlled release tablet in group-hole released way and preparation method thereof
DK2432454T3 (en) 2009-05-19 2017-06-19 Neuroderm Ltd COMPOSITIONS FOR CONTINUOUS ADMINISTRATION OF DOPA DECARBOXYLASE INHIBITORS
CA2775890C (en) 2009-09-30 2016-06-21 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
US8623409B1 (en) 2010-10-20 2014-01-07 Tris Pharma Inc. Clonidine formulation
PL3326615T3 (en) 2010-11-15 2020-07-27 Neuroderm Ltd Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same
EP2481411A1 (en) * 2011-01-27 2012-08-01 Ratiopharm GmbH Oral dosage forms for modified release comprising the JAK3 inhibitor tasocitinib
HUE042425T2 (en) 2012-06-05 2019-06-28 Neuroderm Ltd Compositions comprising apomorphine and organic acids and uses thereof
PL2872121T3 (en) 2012-07-12 2019-02-28 SpecGx LLC Extended release, abuse deterrent pharmaceutical compositions
AU2013302657B2 (en) 2012-08-15 2018-08-09 Tris Pharma, Inc. Methylphenidate extended release chewable tablet
EP4299128A3 (en) 2014-03-13 2024-04-17 Neuroderm Ltd. Dopa decarboxylase inhibitor compositions
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
US11918689B1 (en) 2020-07-28 2024-03-05 Tris Pharma Inc Liquid clonidine extended release composition
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USB587055I5 (en) * 1956-05-24
US4557925A (en) 1982-07-08 1985-12-10 Ab Ferrosan Membrane-coated sustained-release tablets and method
US4629619A (en) * 1984-09-05 1986-12-16 Ab Ferrosan Membrane-coated sustained-release tablets and method
SE8803822D0 (en) * 1988-10-26 1988-10-26 NOVEL DOSAGE FORM
US5376383A (en) 1988-11-21 1994-12-27 Merck & Co., Inc. Method for enhancing the lowering of plasma-cholesterol levels
US5126146A (en) * 1989-10-23 1992-06-30 Merck & Co., Inc. Cellulosic coating
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5324351A (en) * 1992-08-13 1994-06-28 Euroceltique Aqueous dispersions of zein and preparation thereof
US5500227A (en) * 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
US6207190B1 (en) * 1998-08-13 2001-03-27 Chronorx, Llc Dosage forms for the treatment of the chronic glaucomas

Also Published As

Publication number Publication date
EP1267842B1 (en) 2004-11-03
US20010038853A1 (en) 2001-11-08
JP2003528910A (en) 2003-09-30
DE60106889D1 (en) 2004-12-09
EP1267842A1 (en) 2003-01-02
ATE281156T1 (en) 2004-11-15
EP1516616A1 (en) 2005-03-23
US6974591B2 (en) 2005-12-13
US20060159755A1 (en) 2006-07-20
JP4963767B2 (en) 2012-06-27
SE0001151D0 (en) 2000-03-31
DE60106889T2 (en) 2006-03-23
WO2001074336A1 (en) 2001-10-11

Similar Documents

Publication Publication Date Title
AU2001239658A1 (en) Method for producing a controlled-release preparation
EP0650353A4 (en) Palatable pharmaceutical compositions.
FI950319A (en) Morphine controlled release formulation
DE60034565D1 (en) METHOD FOR PRODUCING A COATED TASTE-MASKED GRANULATE WITH IMMEDIATE ACTIVE INGREDIENT EXTRACTION
ATE355829T1 (en) SOLID PHARMACEUTICAL COMPOSITION CONTAINING A LIPOPHILIC ACTIVE INGREDIENT AND THE PRODUCTION THEREOF
ES2153498T3 (en) PROCESS TO PREPARE SOLID PHARMACEUTICAL DOSAGE FORMS.
WO2007054976A3 (en) Lipid based controlled release pharmaceutical composition
AU1729397A (en) Process to prepare soluble delivery systems using volatile salts
ATE342714T1 (en) METHOD FOR PRODUCING ORAL CALCIUM COMPOSITIONS
EP0377517A3 (en) Theophylline dosage form
EE200100161A (en) Slow-release multiparticulates and processes for their preparation
AU3533395A (en) Oral sustained-release preparation
HK1077514A1 (en) Taste-masking coated particles, process for the preparation thereof and orodispersible tablets containing said coated particles
WO2003035051A3 (en) The use of proton sequestering agents in drug formulations
AU2001291526A1 (en) Sustained release composition containing clarithromycin
WO2003002091A3 (en) Sustained-release composition comprising lactic acid-glycolic acid copolymer and process for producing the same
DE60211769D1 (en) A process for the preparation of drug granules, the drug granules and pharmaceutical compositions containing them
ATE288271T1 (en) STABLE SOLID FORMULATION OF AN ENALAPRIL SALT AND METHOD FOR THE PRODUCTION THEREOF
HUP0400799A2 (en) Pharmaceutical formulation having a masked taste and method for the production thereof
WO2004066984A3 (en) Improved taste masking pharmaceutical composition and process for its preparation
EP1258254A4 (en) Sustained release preparations of physiologically active compound hardly soluble in water and production process and use of the same
PL344314A1 (en) Multiparticulate pharmaceutical form with programmed and timed release and preparation method
CA2320878A1 (en) Morphine sulphate microgranules, method for making same and pharmaceutical preparations
EP1417960A4 (en) Sustained release micropellets and process for producing the same
AU7569796A (en) Multivalent polymers, processes for their preparation, and their use for preparing biologically active compounds.